Introduction/Purpose: The aim of surgery for osteochondral lesion of talus is to restore the damaged articular surface with a nearly normal cartilage and supporting subchondral bone. The operative treatment paradigms are still controversial. Though arthroscopic bone-marrow stimulation, autologous osteochondral transplantion and chondrocyte implantation have been performed, but the limitations of these techniques necessitate innovative methods such as cell-based treatment. We investigated the safety and efficacy of human umbilical cord-blood derived mesenchymal stem cell product (CartistemTM) in the treatment of symptomatic osteochondral lesion of the talus.
